India-Manufactured Cough Syrups Under WHO Scanner

India-Manufactured Cough Syrups Under WHO Scanner

Several India-manufactured cough syrups were detected with contaminants recently. Of these, four were marketed in Gambia, two in Uzbekistan, and one in the Marshall Islands and Micronesia. The World Health Organization (WHO) has issued alerts against the use of these formulations.

Overall, seven Indian cough syrups have been rejected over the past seven months India; major contaminants identified were – diethylene glycol and ethylene glycol, known toxic compounds that can be fatal. The syrups were classified substandard as they failed to meet quality standards and safety specifications. 

On April 25th, the WHO issued an alert against a batch of Guaifenesin Syrup TG Syrup, exported to the Marshall Islands and Micronesia, which was categorized contaminated and substandard due to the presence of diethylene glycol and ethylene glycol. Other WHO-issued alerts have been directed against the cough syrups – Ambronol syrup, DOK-1 Max syrup, Kofexmalin Baby Cough Syrup, Magrip N Cold Syrup, Makoff Baby Cough Syrup, and Promethazine Oral Solution.

The manufacturer – QP Pharmachem Ltd, Punjab, India, and the marketer – Trillium Pharma, Haryana, India, are to blame for the sale of these contaminated cough syrups. However, neither had guaranteed the safety and quality of their products. The WHO reported that contaminated Guaifenesin syrup could have gained marketing authorization in certain Western-Pacific countries and were likely distributed to other regions through informal markets.

Last year, the WHO had alerted against substandard cough syrups identified in Gambia – by Maiden Pharmaceuticals Limited, Haryana, India. Early this year, two contaminated cough syrups by Marion Biotech Limited, Uttar Pradesh, India were found contaminated in Uzbekistan.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks